Tracking David Einhorn's Greenlight Capital Portfolio - Q1 2026 Update
Coya Therapeutics Inc COYA
$4.19
▲ +2.70%
(+$0.11)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$4.08
Prev Close
$4.08
Day Range
$4.00 – $4.22
52W Range
$3.71 – $7.75
Market Cap
$98.29M
Beta
0.60
EPS (TTM)
$-1.15
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-12-29 |
| Shares Out. | 23,460,000 |
| Website | coyatherapeutics.com/ ↗ |
| Phone | 18009279800 |
| Employees | 8 |
| Revenue | $251,147 |
| Gross Profit | $251,147 |
| Net Income | -$7.2M |
| Total Assets | $53.3M |
| Total Liabilities | $4.3M |
| Equity | $49.0M |
About Coya Therapeutics Inc
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Coya Therapeutics Inc is a publicly traded company under the ticker symbol COYA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)